2022 Prostate Cancer and Cardiovascular Disease Principles of Optimal Multidisciplinary Management in Clinical Practice - PART 2
This will be a series of four 1-hour webinars that will be online enduring material (4.0 credits total). Each webinar will have its own moderator and faculty, as well as discussion sessions following the lectures/case studies. The overall purpose of this educational program is to discuss state-of-the-art and recent advances in the care of men with prostate cancer and to enhance learners’ knowledge and competency to incorporate evidence-based updates in clinical practice. This is Part 2 of 4 webinars. The launch dates are in May, July, September and November 2022.
This session will cover management issues in patients biochemical relapse following definitive therapy, and metastatic disease (hormone-sensitive and castrate-resistant).
- Pivotal trials that have changed my practice.
Ricardo Rendon, MD
Professor, Department of Urology,
Dalhousie University, Canada
- The role of different hormonal based therapies in Prostate Cancer.
Alicia Morgans, MD, MPH
Genitourinary Medical Oncologist
Medical Director of the Survivorship Program
Dana-Farber Cancer Institute, USA
- Summarizing the CV toxicities for prostate cancer therapies (including the PRONOUNCE trial).
Renato Lopes, MD, PhD
Professor of Medicine
Member in the Duke Clinical Research Institute, USA
- Discussion/question and answer, 15 minutes
The overall purpose of this event is to discuss state-of-the-art and recent advances in the care of men with prostate cancer with an emphasis on CVD disease prevention and optimal management while striving to enhance learners’ knowledge and competency to incorporate evidence-based updates in clinical practice. At the conclusion of this activity, participants should be able to:
- Explain the CV risks and benefits of different management strategies for men with newly diagnosed prostate cancer
- Relate contemporary outcomes following prostatectomy and the principles surrounding optimal patient selection
- Discuss the importance of cardiovascular risk factors in men with prostate cancer and how these might be addressed
- Name recent practice-changing clinical trials in the management of advanced prostate cancer
- Describe the role of adjuvant androgen deprivation therapy in patients undergoing radiotherapy for prostate cancer and the potential impact on the CV system
- Discuss challenging management dilemmas incorporating the treatment of CVD in men with advanced prostate cancer
- Identify emerging areas of clinical research and themes regarding CVD disease prevention before, during, and after treatment in the care of men with prostate cancer.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Attendance
- 1.00 JA Credit - AH
- 1.00 Approved for AMA PRA Category 1 Credit(s)™